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The induction of autoimmunity by viruses has been attributed to numerous mechanisms. In mice,
coxsackievirus B4 (CB4) induces insulin-dependent diabetes mellitus (IDDM) resembling the final
step of disease progression in humans. The immune response following the viral insult clearly precipitates IDDM. However, the molecular pathway between viral infection and the subsequent activation of T cells specific for islet antigen has not been elucidated. These T cells could become activated through exposure to sequestered antigens released by damaged β cells, or they could have
responded to factors secreted by the inflammatory response itself. To distinguish between these possibilities, we treated mice harboring a diabetogenic T cell repertoire with either the islet-damaging
agent streptozotocin (STZ) or poly I:C, which nonspecifically activates T cells. Significantly, only
treatment of mice with STZ resulted in IDDM and mimicked the effects observed following CB4
infection. Furthermore, antigen-presenting cells from STZ-treated mice were shown to directly activate autoreactive T cells and induce diabetes. Therefore, the primary role of CB4 in the precipitation
of IDDM is to damage tissue, causing release and presentation of sequestered islet antigen. These
events stimulate autoreactive T cells and thereby initiate disease.
J. Clin. Invest. 109:79–87 (2002). DOI:10.1172/JCI200211198.

Introduction
Coxsackieviruses have long been associated with the
development of insulin-dependent diabetes mellitus
(IDDM) (1–4). Understanding how coxsackieviruses
mediate diabetes has been complicated by this virus’s
unique tropism for the pancreas as well as the apparent
molecular similarity between the viral P2C gene product of the B4 strain (CB4) and the pancreatic islet antigen GAD65 (5). Recently, the mechanistic role of this
virus was dissected by infecting mice representing different experimental models of diabetes (6), and the
results favored a mechanism of T cell activation
through bystander damage over induction through
molecular mimicry. CB4 infection of NOD mice, which
carry the NOD MHC allele to which presentation of
the cross-reactive epitope is restricted, did not enhance
or change the onset or progression of diabetes. Additionally, no proliferative response to either of the crossreactive epitopes of P2C or GAD was observed following infection. However, CB4 infection of BDC2.5
transgenic (Tg) mice, which harbor a transgene encoding a diabetogenic T cell receptor (TCR) specific to an
islet granule antigen other than GAD65 (7) and not
cross-reactive with CB4, resulted in the rapid onset of
diabetes (6). In our colony, BDC2.5 Tg mice develop
peri-insulitis at an accelerated rate but do not progress
to spontaneous diabetes. CB4 infection activated the
Tg memory T cell population prior to disease onset,
precipitating clinical diabetes in these mice.
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Whether memory T cells can be activated due to the
release of sequestered antigen from the damaged tissue
or simply by cytokine induction following viral infection remained as an important question. To address
this possibility, BDC mice were infected with lymphocytic choriomeningitis virus (LCMV), which can crossactivate nonspecific resting memory lymphocytes during infection but does not destroy islet cells. LCMV
infection did not induce diabetes nor any increase in
insulitis (6). Therefore, viral expansion of nonspecific
T cell responses through cytokine induction is most
likely not activating islet-specific memory T cells to
mediate disease. Yet, the dynamics of the LCMV infection may somehow suppress (8, 9) or interfere with
(10–12) disease development.
To more completely distinguish between the mechanisms that account for coxsackievirus-mediated IDDM,
we treated BDC2.5 mice with two environmental agents
that mimic aspects of viral infection. Treatment with
poly I:C effectively induces type 1 cytokine activation
similar to that observed following viral infection (13).
Alternatively, administration of a single subdiabetogenic dose of streptozotocin (STZ) directly damages
β cells in the pancreatic islets of Langerhans with only
minimal immune cell involvement (14–17). If coxsackievirus induces IDDM through damage to β cells, antigen release, and activation of self-reactive T cells, then
treatment of BDC2.5 Tg mice with STZ and not poly I:C
should activate the resting anti-islet memory T cells,
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leading to the rapid development of diabetes. If, however, viral infection merely activates the resting autoreactive T cells via a cytokine response, then poly I:C treatment alone should be sufficient to induce disease.

Methods
Mice and virus. NOD/Shi and NODSCID mice were
obtained from the rodent breeding colony at The
Scripps Research Institute. BDC2.5 Tg mice were a gift
from Diane Mathis (Joslin Diabetes Center, Harvard
University, Boston, Massachusetts, USA; formerly of
Institut de Genetique et de Biologie Moleculaire,
Strassbourg, France) and have been maintained and
bred to NOD/Shi in our mouse colony. Virus stocks of
coxsackievirus group B type 4 Edwards strain 2 (CB4
strain E2) were obtained from Charles Gauntt (U. of
Texas–San Antonio, San Antonio, Texas, USA) and
were derived from stocks obtained from Roger Loria
(Medical College of Virginia, Commonwealth University of Virginia, Richmond, Virginia, USA; ref. 3). CB4
was originally isolated from patients with IDDM, passaged through murine pancreatic β cells, and subsequently found to induce a diabetes-like disease in mice
(3, 4). Virus stocks of CB4 strain E2 were prepared and
titered as previously described (18). Mice were infected
at 12 weeks of age intraperitoneally with 100 plaqueforming units (pfu) of CB4. Mice were treated with 100
µg per mouse of poly I:C (Sigma Chemical Co., St.
Louis, Missouri, USA) in PBS with an intraperitoneal
injection. Mice were treated with STZ (Sigma Chemical
Co.) at various concentrations as indicated in the text.
STZ was prepared in citrate buffer immediately prior
to intraperitoneal injection. Blood glucose was measured in tail vein or eye bleeds from nonfasting mice at
various times from 1–28 days postinfection or posttreatment on a standard glucometer with a range of
20–400 mg/dl. Mice were considered diabetic when two
or more consecutive readings (24 hours apart) were
greater than 300 mg/d.
Immunohistochemical staining. Organs were removed
and placed in 10% formaldehyde, then processed for
paraffin sectioning. Alternatively, organs were snapfrozen in OCT on dry ice. Immunohistochemistry was
performed on 4-µm–thick paraffin sections for insulin
staining or 7-µm cryocut sections for the other antibodies that were prepared and blocked with avidin and
biotin (Vector Laboratories Inc., Burlingame, California, USA). The primary antibodies were to insulin
(DAKO Corp., Carpinteria, California, USA), F4/80
(Serotec Inc., Washington, DC, USA), CD4 and CD25
(PharMingen, La Jolla, California, USA), and the secondary antibody was a biotinylated anti–guinea pig
IgG (for insulin staining) or anti-rat IgG (for the other
antibodies) used in conjunction with Vectastain ABC
(peroxidase) kits (Vector Laboratories Inc., Carpinteria,
CA). Staining was detected using diaminobenzidine as
a chromagen. Sections were counterstained in Mayer’s
hematoxylin (Sigma Chemical Co.) and mounted in
Permount (Fisher Scientific Co., Pittsburgh, Pennsyl80
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vania, USA). Quantitation of the degree of pancreatic
insulitis was evaluated using both anti-insulin–stained
and multiple hematoxylin and eosin–stained pancreatic sections from infected and uninfected, age-matched
NOD and BDC2.5 Tg mice, and the mice were scored
for peri-insulitis and insulitis. Statistical analysis using
χ-square tests were done on paired groups.
FACS analysis. Peripheral blood was obtained from
mice before and 1 week after treatment with STZ or
poly I:C. Erythrocytes were lyzed by NH4Cl treatment
and lymphocytes incubated with phycoerythrin-labeled
(PE-labeled) antibody to the TCR variable chain Vβ4
and Cy-chrome–labeled CD4 (PharMingen), and FITClabeled antibody to CD25 (Sigma Chemical Co.),
CD44, or CD69 (PharMingen). Cells were fixed in 1%
paraformaldehyde and analyzed with a Becton Dickinson FACS. A minimum of 200,000 events were analyzed
for each sample.
Proliferation assays. Antigen-presenting cells (APCs)
were enriched from the spleens of untreated and STZtreated NOD and NODSCID mice by plastic adherence
as previously described (19). Briefly, spleens were harvested and forced through mesh screens to generate single cell suspensions. Erythrocytes were lysed by NH4Cl
treatment, and the remaining cells were resuspended in
RPMI with 10% FCS at 10 million cells per milliliter.
Cells were incubated on Petri dishes for 3 hours (37°C,
5% CO2). Afterwards, nonadherent cells were removed
by multiple washes with RPMI. Adherent cells were
removed by scraping, counted, and placed in appropriate media for use in either T cell proliferation assays or
adoptive transfer. For proliferation assays, the APCenriched population was irradiated (15 Gy).
For T cell proliferation assays, spleens from untreated BDC2.5 TCR Tg mice were harvested, and erythrocytes were removed and cultured in triplicate on 96well plates at 2 × 105 cells per well in HL-1 media. To
the BDC splenocytes, in triplicate, varying amounts of
adherent cells were added (0, 1.25 × 104, 2.5 × 104,
5 × 104, or 10 × 104 cells). Additionally, triplicate controls with added APCs and peptide (20) (7 µM) were
performed. Cultures were incubated for 2 days at 37°C
and pulsed for 18 hours before harvest with 1 µCi
3H-thymidine. Incorporated 3H was measured using a
liquid scintillation counter. The stimulation index was
calculated for each splenocyte/APC sample, as compared with control wells incubated on the same plate
but lacking any additional adherent cells or antigen.
Adoptive transfer. Donors were either 12-week-old
untreated BDC2.5 TCR Tg mice or 6- to 8-week-old
untreated or STZ-treated NODSCID mice. From BDC
Tg mice, splenocytes were harvested, single cell suspensions generated, and erythrocytes removed, counted, and
transferred at 2 × 106 to 5 × 106 cells per mouse. Recipient mice for the BDC splenocytes were NODSCID mice
that had been treated with either STZ or PBS 7 days
before. Alternatively, splenocytes from treated NODSCID mice were harvested and enriched for APCs by
adherence to plastic as described above. APCs were trans-
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ferred into untreated 12-week-old BDC mice at 5 × 105
to 10 × 105 cells per mouse. Mice were monitored weekly for changes in blood glucose.

Results and Discussion
Prior work has established the ability of poly I:C, a double-stranded nucleic acid, to invoke a type 1 IFN antiviral response without the accompanying damage of a
viral infection (21). Additional work by Tough et al.
(13) had shown that poly I:C treatment could act similarly to LCMV infection and stimulate nonspecific
memory T cells. Whether these activated T cells could
then participate in an autoimmune or pathologic
response has been controversial. To examine whether
the upregulation of the type 1 IFN pathway could
induce IDDM through stimulation of memory T cells,
we treated BDC2.5 Tg mice with poly I:C (100 µg per
mouse) and monitored for disease onset. While CB4
induces diabetes in 67% of the infected BDC2.5 Tg mice
within 4 weeks, poly I:C treatment was unable to
induce clinical disease (Figure 1a). The IFN response to
poly I:C was comparable to that observed following
LCMV infection, as IFN-γ levels were similar in mice 3
days after treatment or infection as measured by ELISA
(350 ng/ml). To establish whether treatment was able
to increase the level of insulitis without inducing diabetes, we stained pancreatic tissue sections with
insulin-specific antibody to demonstrate any loss of
insulin-containing β cells. However, no increase in the
level of peri-insulitis or insulitis was observed following treatment (Table 1). No histological changes were

observed in the pancreas between age-matched treated
and untreated BDC2.5 Tg mice (Figure 2a). To determine whether poly I:C treatment was able to activate
lymphocytes in the BDC2.5 Tg mouse, lymphocytes
were isolated from treated and untreated mice and
stained with antibodies to cell surface molecules for
analysis by flow cytometry. Although none of the CD4+
Vβ4+ (Tg TCR) lymphocytes showed changes in CD25,
CD44, or CD69, indicating a lack of activation, the
CD4– Vβ4+ T cell subset, representing primarily CD8+ T
lymphocytes, demonstrated upregulation of these
markers, denoting their activation (Figure 3a). Therefore, treatment of BDC2.5 Tg mice with poly I:C was
comparable to infection with the noncytopathic virus,
LCMV, and in neither case were the resting memory Tg
CD4+ cells activated or disease induced.
Treatment with a single subdiabetogenic dose of STZ
damages β cells directly with only minimal immune cell
involvement (14–17). While a multiple high- or low-dose
regime of STZ leaves the mouse without functional
β cells and induces autoimmune diabetes, a single lowdose treatment causes significantly less damage and does
not induce clinical disease (14, 15, 17). During coxsackievirus infection of most mouse strains, limited damage
to the β cells is observed. The loss of a few β cells is most
likely counterbalanced by the limited ability of β cells to
regenerate. To mimic the minimal level of viral damage
to the islet, mice would need to be treated with a single
low dose of STZ that would damage only a few β cells,
leaving the majority of insulin-producing cells intact
without altering clinical disease incidence on its own.

Figure 1
(a) Incidence of diabetes in BDC2.5 mice following poly I:C treatment. BDC Tg mice and nontransgenic littermate controls were treated with
100 µg of poly I:C. Alternatively, BDC Tg mice were infected with 100 pfu of CB4. Mice were monitored twice weekly for blood glucose, and
mice with two consecutive values over 300 mg/dl were considered diabetic. Both BDC2.5 mice (n = 12) and their nontransgenic littermates
(n = 12) were analyzed and compared with untreated BDC Tg mice (n = 20). (b) Incidence of diabetes in BDC2.5 mice following STZ treatment. BDC Tg mice and nontransgenic littermates were treated with single doses of 0, 40, 80, or 160 mg/kg of STZ. Mice were monitored
twice weekly for blood glucose, and mice with two consecutive values over 300 mg/dl were considered diabetic. (c) Incidence of diabetes in
NOD/Shi mice following STZ treatment. Twelve-week-old NOD/Shi mice (n = 29) were treated with 80 mg/kg of STZ. Mice were monitored
twice weekly for blood glucose, and mice with two consecutive values over 300 mg/dl were considered diabetic. Treated mice were analyzed
and compared with untreated NOD/Shi mice (n = 10). Mice from all groups were age matched. Groups from b and c were compared for
statistical significance by standard χ-square tests. Of the relevant comparisons, significant differences were observed between STZ-treated
(80 mg/kg) BDC mice and STZ-treated (80 mg/kg) NOD mice at both 2 (P < 0.001) and 4 (P < 0.001) weeks after treatment.
The Journal of Clinical Investigation
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Table 1
Summary of histological analysis of pancreatic sections
from treated mice

Poly I:C - BDCs
STZ - BDCs
Untreated - BDCs

Peri-insulitis

Insulitis

Total islets

43%
7%
42%

42%
85%
56%

124
114
113

Mice were sacrificed 4 weeks after treatment with poly I:C or STZ and examined for peri-insulitis and insulitis. Islets were scored for inflammatory cells as
clean, peri-insulitis, or insulitis. Mice were matched for age and sex. Over 100
islets were scored per group. Scored groups were compared for statistical significance by standard χ-square tests. Of the relevant comparisons, significant
differences were observed for both peri-insulitis (P < 0.001) and insulitis
(P < 0.001) between STZ-treated BDC mice and untreated BDC mice or poly
I:C–treated BDC mice. Additionally, no significant difference was observed
between poly I:C–treated and untreated BDC mice.

For this purpose, a pilot study was performed with a single treatment of STZ. One of three concentrations of
STZ, 40, 80, or 160 mg/kg, was administrated and mice
were monitored for clinical disease. Initial treatments
with STZ clearly indicated that induction of diabetes was
dose-dependent (Figure 1b), and a single dose of 80
mg/kg was chosen for further study. After administration of 80 mg/kg of STZ, BDC2.5 Tg mice developed
IDDM in a manner and time frame similar to that
induced by CB4 infection of BDC2.5 Tg mice (Figure
1b). That is, 67% of the mice became diabetic within 2–4
weeks of treatment. To ensure that this was not an effect
of the NOD MHC background, since this murine strain
spontaneously develops diabetes, a large cohort of agematched (12-week-old) female NOD mice were treated
simultaneously (Figure 1c). The NOD mice had a slight
increase in the incidence of diabetes compared with that
of spontaneous disease in our colony, but this incidence
of STZ-induced NOD disease was significantly lower
than that in the BDC2.5 Tg treated mice (P < 0.001).
STZ-treated BDC2.5 Tg mice had a marked loss of
insulin-producing β cells, which was accompanied by a
dramatic rise in insulitis. The quantitated insulitis index
showed a significant increase (P < 0.001) that coincided
with the onset of diabetes (Table 1). To characterize the
nature of these infiltrating lymphocytes, tissue sections
were immunostained with antibody to CD4, CD25 (Figure 2b), and Vβ4 (data not shown). The infiltrating cells
were predominantly CD4+ lymphocytes and a sizable
percentage of the infiltrating population was indeed
CD25+ or IL-2 receptor–positive, reflecting an activated
state (Figure 2b). As we had observed previously in the
islets of CB4-infected mice (6), the predominant cell
type was indeed the transgenic T cell and therefore both
CD4+ and Vβ4+. Additionally, while loss of insulin staining in β cells without strong insulitis is a common event
in STZ-treated NOD mice (Figure 2a), this was not the
case in the STZ-treated BDC mice since loss of insulin
production by β cells was closely associated with
immune cell infiltration and insulitis. This outcome
strongly suggests that resting memory T cells become
activated due to the release of sequestered antigen during the environmental insult.
82
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Local increases of activated macrophages in pancreatic islets accompany the progression of insulitis in
mice developing diabetes (22, 23). This sequence is
clearly visible in both NOD mice developing spontaneous diabetes and CB4-infected BDC Tg mice. Following single-dose STZ treatment of NOD mice,
insulin production decreased without significant
insulitis (Figure 2a). Consequently, fewer activated
macrophages were present in the affected islets. To
determine whether the islets of the STZ-treated BDC
mice were phenotypically similar to the islets from
virus-infected mice, pancreatic tissue sections were
immunostained with F4/80 antibody to locate activated macrophages. As depicted in Figure 2c, the presence
of macrophages in the islets of STZ-treated BDC mice
closely resembled the situation in the islets of CB4infected BDC mice. In contrast, BDC mice treated with
poly I:C and NOD mice given STZ did not exhibit pronounced insulitis, nor was there any significant
increase in activated macrophages.
To correlate the shift in state from resting to activation in the transgenic Vβ4+ lymphocytes with the
increase in insulitis and onset of diabetes, lymphocytes
were isolated from the spleens and pancreatic lymph
nodes of treated and untreated BDC2.5 mice and
stained with antibodies to cell surface molecules
including Vβ4 (Tg TCR), IL-2 receptor (CD25), CD44,
CD69, and L-selectin (CD62L) for analysis by flow
cytometry. As previously reported, the predominant
phenotype of the transgenic CD4+ Vβ4+ population of
T cells signified resting memory as demonstrated by
high expression of CD44 and absence of expression of
CD25, CD69 (Figure 3b), and CD62L (data not shown).
Strikingly, five days after STZ treatment, transgenic
lymphocytes were activated, as confirmed by the
increased numbers of Vβ4+ lymphocytes staining for
the activation markers CD25 and CD69, as well as the
memory and activation marker CD44 (Figure 3). However, NOD mice had no obvious increase in activation
in CD4+ T cells following STZ treatment. Additionally,
similar STZ treatments of OT-II TCR Tg mice that
express an MHC class II restricted TCR specific for
ovalbumin (24) did not activate T cells when measured
by a similar FACS analysis for upregulation of the activation markers CD25, CD44, or CD69 (data not
shown). Thus, the single low-dose treatment of STZ is
acting solely as a β cell toxin and did not directly activate T cells. The shift in T cell activation by a significant
portion of Vβ4+ cells correlated with the rapid and significant increase in insulitis composed predominantly
of Vβ4+ (Tg) cells, β cell loss, and observed diabetes similar to that observed following CB4 infection. However, in this case, a β cell toxin replaced the virus, further
underscoring the requirement for β cell damage in the
development of IDDM.
The ability of STZ to elicit diabetes with kinetics and
phenotype similar to those of diabetes elicited by CB4
infection demonstrates that virus-mediated diabetes is
the result of direct damage to the β cells followed by
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activation of an autoreactive memory response that
attacks and destroys the islets. The direct damage of
β cells associated with either the single low-dose STZ
(at 80 mg/kg) treatment or CB4 infection is, by itself,
not sufficient to cause diabetes, since nontransgenic
mice show little enhancement in disease. However, in
both instances, sufficient β cell damage occurs to
allow for release of sequestered β cell antigen and stimulation of the resting memory T cell population. This
result, most likely, reflects the ability of pancreatic
APCs to process and present β cell antigen and thereby stimulate the BDC T cell.

To demonstrate that APCs take up islet antigen and
stimulate the BDC T cells, we performed in vitro proliferation assays. APCs were enriched using plastic
adherence from mice either treated or not treated with
STZ; BDC T cells from untreated mice were then cocultivated with these APCs. As a control, APCs from
untreated mice were cultured with BDC T cells and
antigenic peptide (20). Previous work has demonstrated that enriched APCs can harbor antigen following
viral infection or during local pathogenic inflammation and can present this antigen in in vitro proliferation assays (19, 25–27). In this situation, the pancreat-

Figure 2
(a) Histological analysis of pancreata of treated BDC Tg and NOD mice. Representative sections of the pancreas from STZ-treated BDC Tg
mice and poly I:C–treated BDC Tg mice reveal islet cell integrity and function. The function of β cells was confirmed by immunohistochemistry using antibody to insulin (INS) (×400), present as brown staining. Mice were sacrificed at 2 weeks after treatment. (b) Immunohistological analysis of the islets from treated BDC Tg mice for activated T cells. Representative immunostained sections of islets from the
pancreas of either STZ- or poly I:C–treated BDC Tg mice. Immunohistochemical staining for either CD4 or CD25 was performed and revealed
CD4+ lymphocytes in both mice, but only STZ-treated mice have activated CD4+ cells as demonstrated by CD25 staining. Immunostained
cells are brown (×400). The mice were sacrificed at 14 days after treatment. (c) Immunohistological analysis of pancreata from treated BDC
Tg and NOD mice for macrophages. Representative immunostained sections of the pancreas from CB4-infected and STZ- and poly I:C–treated BDC Tg and NOD mice reveal differences in the number and activation state of resident macrophages. Antibody to the macrophage activation marker F4/80 was used to identify activated macrophages, which, following CB4 infection and STZ treatment of BDC Tg mice, appear
to become activated in the peri-insular inflammation and to mobilize into the islets of Langerhans during insulitis (×400). Brown antimacrophage staining is present over macrophages. Mice were sacrificed 2 weeks after infection or treatment.
The Journal of Clinical Investigation
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Figure 3
Analysis of the activation state of lymphocytes from BDC2.5 mice following treatment with either poly I:C (a) or STZ (b). Cells were stained
with antibody to Vβ4 TCR, CD4, and antibody to either CD25, CD44, or CD69. Cells were analyzed by FACS and compared to isotype controls. Shown are histograms of mean fluorescent intensities generated by gating on 10,000–20,000 CD4+, Vβ4+ cells, or Vβ4+, CD4– cells. (a).
For both a and b, the plots are representative of one of six mice analyzed, and all six had similar results. (a) Analysis of peripheral blood lymphocytes before (narrow) and three days following poly I:C treatment (wide) from identical mouse are displayed. No shift of activation is
observed in the Vβ4+, CD4+ T cell population while activation is observed in the Vβ4+, CD4– (CD8+) T cell population posttreatment (PT).
Changes in cell populations and gated markers CD4+, Vβ4+: CD25, 5.7% to 7.2%; CD44-high, 28.6% to 25.2%; CD69, 6.7% to 6.9% and
CD4–, Vβ4+: CD25, 2.9% to 27.8%; CD 44-high, 22.9% to 65.0%; CD69, 10.7% to 41.8%. (b) Analysis of lymphocytes from the spleen and
pancreatic lymph node before (narrow) and seven days following STZ treatment (wide) are displayed. Mice were analyzed at three, five, and
seven days PT. Similar results were observed at five days, but not at three days. A dramatic shift in all three activation markers was observed
in the spleen PT. A less dramatic shift was observed in the pancreatic lymph node.Changes in cell populations and gated markers in spleen
CD4+ Vβ4+ : CD25, 10.4% to 32.9%; CD44-high, 19.8% to 56.5%; CD69, 9.0% to 32.3%; and in pancreatic lymph nodes, CD4+ Vβ4+ : CD25,
5.4% to 25.3%; CD44-high, 7.2% to 18.9%; CD69, 8.7% to 27.0%.

ic inflammation initially induced by the STZ treatment
is minor in comparison to that reported in previous
studies (19, 25–27), yet a subpopulation of APCs from
these STZ-treated mice would be expected to have gathered endogenous islet cell antigen following STZinduced β cell damage. These APCs would be capable
of stimulating BDC T cells in culture to proliferate;
however, stimulation would also induce these APCs to
digest the harbored endogenous β cell antigen rapidly
(28). Additionally, unlike most standard in vitro proliferation assays in which antigen is not continuously
available and is only brought into the culture within
the APC. Therefore, the assay results should give lower
stimulation indices than in the case of provided antigen or the peptide control. Additionally, the assay
would peak in stimulation at a much earlier time point.
In fact this was the case: the stimulation index peaked
at day 3 of coculture and the index averaged about 4 for
mice treated with STZ as compared with 1 for APCs
from untreated mice (Figure 4). In the absence of
exogenous antigen, APCs from mice with damaged
β cells were capable of stimulating the β cell–specific
BDC T cell, while APCs from mice without β cell damage did not stimulate these T cells. Therefore, following an insult to the pancreatic islets, the ability of the
APC to process and present β cell antigen to the BDC
T cell is crucial to T cell activation.
To further demonstrate the importance of APC presentation and stimulation of T cells during the development of diabetes, adoptive transfer experiments
were performed (Table 2). APCs enriched from STZtreated NODSCID mice induced diabetes when trans84
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ferred into naive BDC TCR Tg mice, while APCs from
untreated mice did not induce disease. Conversely, to
determine whether STZ treatment could prime mice
for the development of disease, we transferred BDC2.5
Tg T cells into STZ-treated recipients. The experiments
showed that splenocytes from BDC TCR Tg mice
induced rapid diabetes when transferred into STZtreated NODSCID mice. Splenocytes from BDC TCR
Tg mice typically induce IDDM in NODSCID mice
following transfer, but at a much slower rate and rarely
before 4 weeks after transfer. Therefore the development of diabetes is the direct result of APCs presenting islet antigen from STZ-induced β cell damage and
activating BDC T cells.
In BDC Tg mice, the autoreactive resting memory T
cells are provided by transgenic technology. Development of this resting memory population of lymphocytes in prediabetic patients is, quite possibly, the consequence of previous pancreatropic infections. Whether
given virus or STZ, the BDC Tg mice develop diabetes
with similar kinetics, incidence, and severity. Taken
together these data support the argument that diabetes
is a result of environmental damage to the β cells.
Alternatively, inflammation from environmental
insults like CB4 or STZ could stimulate the BDC TCR
through a second TCR expressed with a different or
nontransgenic Vα chain. The ability of the endogenous
Vα chain to avoid allelic exclusion and to recombine,
be expressed, and interact with the transgenic Vβ chain
has been well described (29–31). However, when these
same BDC mice were crossed with another TCR Tg
mouse to determine whether activation of the second
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Figure 4
Presentation of endogenous antigen by APCs from STZ-treated mice
activates β cell–specific BDC T cells. Adherent mononuclear cells
from NOD mice treated with STZ or PBS were prepared, irradiated,
and cultured with BDC2.5 Tg splenocytes (2 × 105) at various ratios.
Shown is a summary of results from the 4:1 ratio, T cell (2 × 105):
APC (5 × 104). Also shown are the results of culturing these cells at
4:1 in the presence of antigenic peptide (7 µM) (20) specific for the
BDC T cell. Cultures were pulsed with 1 µCi of 3H thymidine at 48
hours and harvested 18 hours thereafter. The data presented are
from four separate experiments involving a total of eight mice in each
group representing the APC populations. Values are presented as
stimulation index + SEM as compared with BDC splenocytes incubated without additional APCs or antigen. Background in all experiments was between 500 and 2500 cpm.

TCR could activate BDC T cells, the results convincingly demonstrated that this could not occur in vivo
to induce diabetes (32). One experimental drawback of
this system is the lack of knowledge of the true BDCspecific antigen; however, recently, antigenic peptides
have been identified that stimulate the BDC2.5 T (20).
Although the nature of the natural islet autoantigen is
not known, it is clear that an active response from
F4/80-positive cells is required within the islet itself
before disease develops. Activated macrophages or
dendritic cells are most likely picking up released antigen and presenting it to resting memory Tg T cells.
Conversely, STZ-treated NOD mice do not have the
same level of activated F4/80 staining cells and likewise exhibit less insulitis. Further, while APCs isolated
from STZ-treated NOD or NODSCID mice successfully activated the BDC T cell and induced diabetes
(Figure 4), they did not induce disease in NOD mice
(data not shown). Therefore, mere stimulation of
macrophages by STZ or β cell damage does not neces-

sarily activate T cells to induce disease. A critical level
of autoreactive precursor resting memory T cells is
most likely required (33, 34). Clearly, once initiated,
the responses of both T cells and APCs amplify each
other and heighten pathologic effects. The requirements of costimulation for this initiation are probably
reduced, since the memory state of the T cells lessens
the priming requirements of these cells.
NOD mice treated with STZ did not exhibit an
increase in diabetes development despite the release of
islet antigen and the prevalence of autoreactive lymphocytes. The major difference between the BDC mice,
in which diabetes is STZ-inducible, and the NOD mice
is the frequency of autoreactive precursor resting
memory T cells. The transgenic population consists
primarily of CD4+, CD44-high, CD62L-low islet-specific lymphocytes with few requirements for activation. In the NOD mouse, these autoreactive lymphocytes are present at a much lower frequency. Despite
the predominance of a single specific T cell population, the BDC Tg mouse had enough flexibility to
combat viral infections and counter-regulate its large
number of autoreactive cells. This abnormal T cell
repertoire of the BDC mouse is obviously an exaggerated version of a human preclinical situation.
In patients, genetic predisposition and environmental exposures could lead to a similar expansion of
autoreactive T cells, leading to peri-insulitis. This repertoire could undergo further distortion in response to
viral infection, as has been reported by others (35–37).
Ultimately, release of sequestered antigen by viral infection or environmental insult would be the triggering
event in disease initiation, as observed in the STZ-treated or CB4-infected BDC mouse. It was previously proposed that, in a situation with a distorted lymphocyte
repertoire, infection could shift the balance and result
in a loss of regulatory T cells, allowing disease to occur.
Similarly, viral interference of the host immune regulatory process has been observed in mice with normal
T cell repertoires, and the result was an increased survival rate of nonviral-specific T cells (11, 38, 39). However, a single low dose of STZ (acting in place of CB4)
did not directly activate T cells or interfere with the
turnover or regulation of autoreactive cells. STZ can

Table 2
Transfer of autoimmune diabetes with APCs from mice with damaged β cells
Donor cells

Recipient mice

Weeks post-transfer (% diabetic)

APCs from untreated NODSCID mice
APCs from STZ-treated NODSCID mice (7 days PT)
BDC2.5 TCR Tg splenocytes
BDC2.5 TCR Tg splenocytes

BDC2.5 TCR Tg (n = 9)A
BDC2.5 TCR Tg (n = 9)A
Untreated NODSCID mice (n = 9)A
STZ-treated NODSCID mice
(7 days PT, n = 10)A

1

2

3

4

5

6

0%
11%
0%
60%

0%
33%
0%
70%

0%
33%
0%
70%

0%
33%
44%
80%

0%
33%
44%
90%

0%
33%
55%
90%

Autoimmune diabetes was induced following either adoptive transfer of APCs from mice with damaged β cells or transfer of autoreactive T cells into immunedeficient mice with damaged β cells. Adherent mononuclear cells from NODSCID mice treated with STZ or not treated were adoptively transferred into BDC2.5
Tg mice at a concentration of 5 × 105 to 10 × 105 cells per mouse. Splenocytes from BDC2.5 TCR Tg mice were adoptively transferred into NODSCID mice that
had been STZ-treated or not 7 days previously at a concentration of 2 × 106 to 5 × 106 cells per mouse. Mice with consecutive BG measurements of greater
than 300 mg/dl were considered diabetic. AAge-matched. PT, post-transfer.
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fully replace the virus in IDDM development; thus the
role of CB4 is clearly to damage β cells and not to act as
an immune modulator.
The inability of poly I:C to upregulate the BDC Tg T
cell and initiate disease argues against a role for
bystander T cell amplification in the development of
virus-mediated autoimmune disease. Although viruses have the ability to upregulate nonspecific responses and to enhance disease, this bystander amplification
is subject to limitations in the scope of its involvement. Results from other investigators (40, 41) imply
that an additional factor is required to reactivate lymphocytes and drive autoimmunity. Merely activating
potential autoimmune T cells is not enough to cause
disease. Yet, in some instances, viral cross-activation
has increased the incidence of disease (42, 43). Crossactivation during infection is predominantly associated with CD8+ T cells through the type 1 IFN pathway
and involves IL-15 and the use of the IL-2β receptor
that is specifically found on CD8+, but not CD4+, T
cells. Conversely, CD4+ T cells are not similarly reactivated. This activation of CD8+ T cells by IFN was
induced by IL-15 and appeared to utilize the IL-2
receptor β that is found on CD8+ T cells but not CD4+
T cells (44). Although CD8+ T cells participate in nonspecific cross-activation, systems involving CD4+ lymphocytes, as in coxsackievirus-induced IDDM of
BDC2.5 Tg mice (6), herpes simplex virus-1–induced
herpetic stromal keratitis (45), and pathogen-induced
experimental autoimmune encephalomyelitis (46),
show little cross-activation. In systems dependent on
CD8+ lymphocytes, such as the LCMV transgenic
models (43, 47), systemic cross-activation may be the
only requirement for activating memory CD8+ T cells,
inducing pathogenic T cells and producing disease.
Additionally, in general, CD8+ T cell effectors have
fewer counter-regulatory mechanisms than do CD4+
T cells. In the case of human autoimmune disease, the
actions of CD8+ T cells may, in turn, be more important during relapses and be critical to the development
of both IDDM and multiple sclerosis. Certainly CD4+
and CD8+ T cells are both important participants in
human autoimmune disease. Their reactivation,
apparently via separate mechanisms, is clearly mutually dependent. Differences in the inducibility of diabetes between the BDC2.5 Tg mouse and its NOD littermate further elucidate not only the crucial
importance of breakdown and release of sequestered
antigen, but also the requirement for a sizable preexisting memory population of autoreactive lymphocytes in the development of overt clinical disease.
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